Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Apr 1;3(4):e202507.
doi: 10.1001/jamanetworkopen.2020.2507.

Association of Survival With Chemoendocrine Therapy in Women With Small, Hormone Receptor-Positive, ERBB2-Positive, Node-Negative Breast Cancer

Sung Jun Ma  1 , Oluwadamilola T Oladeru  2 , Anurag K Singh  1
Affiliations
Observational Study

Association of Survival With Chemoendocrine Therapy in Women With Small, Hormone Receptor-Positive, ERBB2-Positive, Node-Negative Breast Cancer

Sung Jun Ma et al. JAMA Netw Open. .

Abstract

This cohort study examines the association of survival with adjuvant chemoendocrine therapy for hormone receptor–positive, ERBB2-positive, node-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Oladeru reported receiving grants from Partners Center of Expertise in Health Policy and Management outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Kaplan-Meier Survival Curves After Matching
Matching was performed for variables, including treatment facility volume, facility type, age, race, income level, comorbidity score, year of diagnosis, histologic profile, tumor grade, number of lymph nodes examined, hormone receptor status, type of surgery and radiation, surgical margin, radiation dose, postoperative readmissions, and duration of postoperative inpatient admission. Graphs show survival curves for patients with tumors smaller than 8 mm (A) and tumors 8 to 10 mm (B) who did or did not receive chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. . High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):-. doi:10.1200/JCO.2009.23.2025 - DOI - PMC - PubMed
    1. Tolaney SM, Guo H, Pernas S, et al. . Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2019;37(22):1868-1875. doi:10.1200/JCO.19.00066 - DOI - PMC - PubMed
    1. National Comprehensive Cancer Network Breast cancer, version 2.2020. Published 2020. Accessed February 9, 2020. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
    1. Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637-1638. doi:10.1001/jama.2015.13480 - DOI - PMC - PubMed
    1. Stitzenberg KB, Chang Y, Smith AB, Nielsen ME. Exploring the burden of inpatient readmissions after major cancer surgery. J Clin Oncol. 2015;33(5):455-464. doi:10.1200/JCO.2014.55.5938 - DOI - PMC - PubMed

Publication types

Substances